NURS 5334 Advanced Pharmacology for Nurse Practitioners Final Exam Actual
Exam 2026/2027 – Comprehensive UTA Update with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Pharmacokinetics & Pharmacodynamics (Questions 1–20)
Q1: A 62-year-old patient is started on a new medication with a half-life of 6 hours. The
nurse practitioner explains that therapeutic steady-state concentration is typically
achieved after how many hours?
A. 12 hours
B. 18 hours
C. 30 hours [CORRECT]
D. 48 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4–5 half-lives (5 ×
6 hours = 30 hours). Options A and B represent only 2–3 half-lives, which is insufficient
for steady-state, while D overestimates the timeframe.
Q2: A patient asks why their oral morphine dose is higher than the intravenous dose
they received in the hospital. The NP explains that this difference is primarily due to
which pharmacokinetic principle?
A. Volume of distribution
B. First-pass hepatic metabolism [CORRECT]
C. Protein binding displacement
D. Active tubular secretion
Correct Answer: B
,Rationale: Oral morphine undergoes significant first-pass hepatic metabolism, reducing
its bioavailability compared to IV administration, necessitating higher oral doses.
Volume of distribution (A) relates to drug distribution in body tissues, not
route-dependent dose differences.
Q3: A 78-year-old patient with low albumin is prescribed warfarin. The NP monitors
closely for toxicity because decreased protein binding leads to which pharmacodynamic
consequence?
A. Increased drug metabolism
B. Increased free (unbound) active drug [CORRECT]
C. Decreased volume of distribution
D. Increased renal excretion
Correct Answer: B
Rationale: Decreased albumin reduces protein binding, increasing the free fraction of
highly protein-bound drugs like warfarin, thereby increasing pharmacologic effect and
toxicity risk. Option A confuses distribution with metabolism.
Q4: Which CYP450 enzyme isoform is responsible for metabolizing approximately 50%
of all clinically used drugs?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes approximately 50% of clinically used drugs and is
involved in many significant drug-drug interactions. CYP2D6 (C) metabolizes about 25%,
while CYP1A2 (A) and CYP2C19 (B) metabolize smaller percentages.
Q5: A drug has a therapeutic index of 2. The NP recognizes this means:
A. The drug is very safe with a wide margin of safety
,B. The toxic dose is twice the effective dose [CORRECT]
C. The drug requires therapeutic drug monitoring
D. The effective dose is half the toxic dose
Correct Answer: B
Rationale: Therapeutic index (TI) = TD50/ED50; a TI of 2 means the toxic dose is only
twice the effective dose, indicating a narrow therapeutic index and increased risk of
toxicity. Option D reverses the relationship.
Q6: A neonate is prescribed phenobarbital. The NP expects dosing adjustments
because neonates have which pharmacokinetic characteristic?
A. Increased hepatic enzyme activity
B. Decreased protein binding and increased free drug [CORRECT]
C. Increased gastric acidity
D. Adult-equivalent renal function
Correct Answer: B
Rationale: Neonates have decreased protein binding (low albumin), leading to increased
free drug concentrations. They also have immature hepatic enzymes (A is wrong), low
gastric acidity (C is wrong), and immature renal function (D is wrong).
Q7: A patient with chronic kidney disease is prescribed a drug primarily excreted
unchanged by the kidneys. The NP should:
A. Increase the dose and extend the dosing interval
B. Reduce the dose or extend the dosing interval [CORRECT]
C. Switch to the intravenous route only
D. Administer with food to enhance absorption
Correct Answer: B
Rationale: In renal impairment, drugs excreted renally accumulate; dose reduction or
extended intervals prevent toxicity. Increasing the dose (A) would worsen accumulation,
and route change (C) does not address excretion.
, Q8: Which term describes the fraction of an administered drug dose that reaches
systemic circulation unchanged?
A. Volume of distribution
B. Clearance
C. Bioavailability [CORRECT]
D. Therapeutic index
Correct Answer: C
Rationale: Bioavailability (F) is the fraction of administered dose reaching systemic
circulation. Volume of distribution (A) describes drug distribution, clearance (B)
describes elimination, and therapeutic index (D) describes safety margin.
Q9: A drug with a large volume of distribution (Vd > 40 L) is most likely to:
A. Be primarily confined to the plasma compartment
B. Be highly lipid-soluble and distribute extensively into tissues [CORRECT]
C. Have high renal clearance
D. Be highly protein-bound
Correct Answer: B
Rationale: A large Vd indicates extensive tissue distribution, typically seen with
lipid-soluble drugs. Drugs confined to plasma (A) have small Vd (~3–5 L), and protein
binding (D) tends to keep drugs in plasma.
Q10: A patient on digoxin has a serum level of 3.2 ng/mL (therapeutic 0.5–2.0 ng/mL).
The NP recognizes this as:
A. A pharmacokinetic error in distribution
B. A pharmacodynamic manifestation of toxicity [CORRECT]
C. An expected therapeutic response
D. A receptor upregulation phenomenon
Correct Answer: B
Exam 2026/2027 – Comprehensive UTA Update with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Pharmacokinetics & Pharmacodynamics (Questions 1–20)
Q1: A 62-year-old patient is started on a new medication with a half-life of 6 hours. The
nurse practitioner explains that therapeutic steady-state concentration is typically
achieved after how many hours?
A. 12 hours
B. 18 hours
C. 30 hours [CORRECT]
D. 48 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4–5 half-lives (5 ×
6 hours = 30 hours). Options A and B represent only 2–3 half-lives, which is insufficient
for steady-state, while D overestimates the timeframe.
Q2: A patient asks why their oral morphine dose is higher than the intravenous dose
they received in the hospital. The NP explains that this difference is primarily due to
which pharmacokinetic principle?
A. Volume of distribution
B. First-pass hepatic metabolism [CORRECT]
C. Protein binding displacement
D. Active tubular secretion
Correct Answer: B
,Rationale: Oral morphine undergoes significant first-pass hepatic metabolism, reducing
its bioavailability compared to IV administration, necessitating higher oral doses.
Volume of distribution (A) relates to drug distribution in body tissues, not
route-dependent dose differences.
Q3: A 78-year-old patient with low albumin is prescribed warfarin. The NP monitors
closely for toxicity because decreased protein binding leads to which pharmacodynamic
consequence?
A. Increased drug metabolism
B. Increased free (unbound) active drug [CORRECT]
C. Decreased volume of distribution
D. Increased renal excretion
Correct Answer: B
Rationale: Decreased albumin reduces protein binding, increasing the free fraction of
highly protein-bound drugs like warfarin, thereby increasing pharmacologic effect and
toxicity risk. Option A confuses distribution with metabolism.
Q4: Which CYP450 enzyme isoform is responsible for metabolizing approximately 50%
of all clinically used drugs?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes approximately 50% of clinically used drugs and is
involved in many significant drug-drug interactions. CYP2D6 (C) metabolizes about 25%,
while CYP1A2 (A) and CYP2C19 (B) metabolize smaller percentages.
Q5: A drug has a therapeutic index of 2. The NP recognizes this means:
A. The drug is very safe with a wide margin of safety
,B. The toxic dose is twice the effective dose [CORRECT]
C. The drug requires therapeutic drug monitoring
D. The effective dose is half the toxic dose
Correct Answer: B
Rationale: Therapeutic index (TI) = TD50/ED50; a TI of 2 means the toxic dose is only
twice the effective dose, indicating a narrow therapeutic index and increased risk of
toxicity. Option D reverses the relationship.
Q6: A neonate is prescribed phenobarbital. The NP expects dosing adjustments
because neonates have which pharmacokinetic characteristic?
A. Increased hepatic enzyme activity
B. Decreased protein binding and increased free drug [CORRECT]
C. Increased gastric acidity
D. Adult-equivalent renal function
Correct Answer: B
Rationale: Neonates have decreased protein binding (low albumin), leading to increased
free drug concentrations. They also have immature hepatic enzymes (A is wrong), low
gastric acidity (C is wrong), and immature renal function (D is wrong).
Q7: A patient with chronic kidney disease is prescribed a drug primarily excreted
unchanged by the kidneys. The NP should:
A. Increase the dose and extend the dosing interval
B. Reduce the dose or extend the dosing interval [CORRECT]
C. Switch to the intravenous route only
D. Administer with food to enhance absorption
Correct Answer: B
Rationale: In renal impairment, drugs excreted renally accumulate; dose reduction or
extended intervals prevent toxicity. Increasing the dose (A) would worsen accumulation,
and route change (C) does not address excretion.
, Q8: Which term describes the fraction of an administered drug dose that reaches
systemic circulation unchanged?
A. Volume of distribution
B. Clearance
C. Bioavailability [CORRECT]
D. Therapeutic index
Correct Answer: C
Rationale: Bioavailability (F) is the fraction of administered dose reaching systemic
circulation. Volume of distribution (A) describes drug distribution, clearance (B)
describes elimination, and therapeutic index (D) describes safety margin.
Q9: A drug with a large volume of distribution (Vd > 40 L) is most likely to:
A. Be primarily confined to the plasma compartment
B. Be highly lipid-soluble and distribute extensively into tissues [CORRECT]
C. Have high renal clearance
D. Be highly protein-bound
Correct Answer: B
Rationale: A large Vd indicates extensive tissue distribution, typically seen with
lipid-soluble drugs. Drugs confined to plasma (A) have small Vd (~3–5 L), and protein
binding (D) tends to keep drugs in plasma.
Q10: A patient on digoxin has a serum level of 3.2 ng/mL (therapeutic 0.5–2.0 ng/mL).
The NP recognizes this as:
A. A pharmacokinetic error in distribution
B. A pharmacodynamic manifestation of toxicity [CORRECT]
C. An expected therapeutic response
D. A receptor upregulation phenomenon
Correct Answer: B
